Skip to main content
OpenTrials

Clinical trial condition

Recurrent Ovarian Cancer

Explore clinical trials studying Recurrent Ovarian Cancer. Study availability and eligibility vary by location and protocol.

32 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Ovarian Cancer trial results

Recruiting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations
  • University of Alabama_6th Ave Birmingham, Alabama, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber / Harvard Cancer Center Boston, Massachusetts, United States
  • Mayo Clinic - Rochester Rochester, Minnesota, United States
View all 52 locations
View Trial Details
Recruiting

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +14 more
Locations
  • University of California Los Angeles /ID# 269339 Los Angeles, California, United States
  • Norton Cancer Institute - St. Matthews /ID# 269070 Louisville, Kentucky, United States
  • Holy Cross Hospital - Silver Spring /ID# 269344 Silver Spring, Maryland, United States
  • Mercy David C. Pratt Cancer Center /ID# 269350 St Louis, Missouri, United States
View all 40 locations
View Trial Details
Recruiting

Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

NCT03458221

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +16 more
Locations
  • Radboudumc Nijmegen, Gelderland, Netherlands
  • Catharina Ziekenhuis Eindhoven, North Brabant, Netherlands
  • Amphia Hospital Breda, Netherlands
  • Maastricht UMC+ Maastricht, Netherlands
View Trial Details

Related conditions